Sun Pharma to buy U.S. drug firm Concert for $576 mn
The upfront payment of $8 per share of common stock in cash represents a premium of around 33% to Concert's 30-day volume weighted average price as of January 18, 2023.
The upfront payment of $8 per share of common stock in cash represents a premium of around 33% to Concert's 30-day volume weighted average price as of January 18, 2023.
